Literature DB >> 28019103

Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch.

Monique Wapenaar1, Amit S Patel2, Surinder S Birring3, Ron T van Domburg4, Eric Wp Bakker5, Virginia Vindigni6, C Magnus Sköld7, Vincent Cottin8, Carlo Vancheri6, Marlies S Wijsenbeek1.   

Abstract

No disease-specific instruments exist in Dutch, French, Italian, and Swedish to measure health status in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). The King's Brief Interstitial Lung Disease (K-BILD) is a 15-item validated questionnaire assessing health status in patients with ILD. The aim of this study was to translate and validate the K-BILD to French, Italian, Swedish, and Dutch versions. The K-BILD was translated following a forward-backward multistep procedure and tested in structured patient interviews. Subsequently, 195 outpatients with ILD were asked to complete K-BILD, St. George's Respiratory Questionnaire (SGRQ), and Euroqol EQ-5D-5L (EQ5D), twice, 2 weeks apart. Internal consistency, concurrent validity, and repeatability were determined. No major difficulties occurred in the translation processes. The K-BILD was considered comprehensible and relevant by patients. One hundred seventy-six patients (108 IPF and 68 other ILDs) completed the translated K-BILD. Internal consistency was good for all K-BILD modules (Cronbach's α 0.70-0.93). Concurrent validity of K-BILD was strong compared with SGRQ ( r = -0.86) and EQ5D ( r = 0.68), low with transfer capacity of the lung for carbon monoxide corrected for hemoglobin ( r = 0.33) and with forced vital capacity ( r = 0.35). The K-BILD and its domains were repeatable over 2 weeks; intraclass correlation coefficients were 0.86-0.93 ( n = 159). Known groups validity showed K-BILD was able to discriminate between patients based on severity of disease. K-BILD's validity and reliability for patients with IPF was similar to that of other ILDs. The French, Italian, Swedish, and Dutch translated K-BILD questionnaires were well-received by patients and demonstrated excellent validity comparable to the original English K-BILD.

Entities:  

Keywords:  Interstitial lung diseases; health status; idiopathic pulmonary fibrosis; quality of life; questionnaires

Mesh:

Year:  2016        PMID: 28019103      PMCID: PMC5720224          DOI: 10.1177/1479972316674425

Source DB:  PubMed          Journal:  Chron Respir Dis        ISSN: 1479-9723            Impact factor:   2.444


  28 in total

1.  Standardisation of the single-breath determination of carbon monoxide uptake in the lung.

Authors:  N Macintyre; R O Crapo; G Viegi; D C Johnson; C P M van der Grinten; V Brusasco; F Burgos; R Casaburi; A Coates; P Enright; P Gustafsson; J Hankinson; R Jensen; R McKay; M R Miller; D Navajas; O F Pedersen; R Pellegrino; J Wanger
Journal:  Eur Respir J       Date:  2005-10       Impact factor: 16.671

2.  Quality criteria were proposed for measurement properties of health status questionnaires.

Authors:  Caroline B Terwee; Sandra D M Bot; Michael R de Boer; Daniëlle A W M van der Windt; Dirk L Knol; Joost Dekker; Lex M Bouter; Henrica C W de Vet
Journal:  J Clin Epidemiol       Date:  2006-08-24       Impact factor: 6.437

3.  Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.

Authors:  B Bradley; H M Branley; J J Egan; M S Greaves; D M Hansell; N K Harrison; N Hirani; R Hubbard; F Lake; A B Millar; W A H Wallace; A U Wells; M K Whyte; M L Wilsher
Journal:  Thorax       Date:  2008-09       Impact factor: 9.139

4.  Medical questionnaires are copyrighted to ensure that validity is maintained.

Authors:  Elizabeth F Juniper
Journal:  Chest       Date:  2009-10       Impact factor: 9.410

5.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.

Authors:  P W Jones; F H Quirk; C M Baveystock; P Littlejohns
Journal:  Am Rev Respir Dis       Date:  1992-06

6.  Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients.

Authors:  Gadi Schoenheit; Ian Becattelli; Alan H Cohen
Journal:  Chron Respir Dis       Date:  2011-08-19       Impact factor: 2.444

Review 7.  Health-related quality of life in idiopathic pulmonary fibrosis: where are we now?

Authors:  Amanda Belkin; Jeffrey J Swigris
Journal:  Curr Opin Pulm Med       Date:  2013-09       Impact factor: 3.155

8.  The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease.

Authors:  Amit S Patel; Richard J Siegert; Gregory J Keir; Sabrina Bajwah; Richard D Barker; Toby M Maher; Elisabetta A Renzoni; Athol U Wells; Irene J Higginson; Surinder S Birring
Journal:  Respir Med       Date:  2013-07-16       Impact factor: 3.415

9.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

Review 10.  The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation.

Authors:  Emma Loveman; Vicky R Copley; Jill L Colquitt; David A Scott; Andy J Clegg; Jeremy Jones; Katherine M A O'Reilly; Sally Singh; Claudia Bausewein; Athol Wells
Journal:  BMC Pharmacol Toxicol       Date:  2014-11-19       Impact factor: 2.483

View more
  3 in total

1.  The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases.

Authors:  Surinder S Birring; Donald M Bushnell; Michael Baldwin; Heiko Mueller; Natalia Male; Klaus B Rohr; Yoshikazu Inoue
Journal:  Eur Respir J       Date:  2022-06-02       Impact factor: 33.795

2.  Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L.

Authors:  Boglárka Lilla Szentes; Michael Kreuter; Thomas Bahmer; Surinder S Birring; Martin Claussen; Julia Waelscher; Reiner Leidl; Larissa Schwarzkopf
Journal:  Respir Res       Date:  2018-05-25

3.  Validation of the King's Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis.

Authors:  Thomas Skovhus Prior; Ole Hilberg; Saher Burhan Shaker; Jesper Rømhild Davidsen; Nils Hoyer; Surinder S Birring; Elisabeth Bendstrup
Journal:  BMC Pulm Med       Date:  2019-12-19       Impact factor: 3.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.